AUTHOR=Izadmehr Sudeh , Lundon Dara J. , Mohamed Nihal , Katims Andrew , Patel Vaibhav , Eilender Benjamin , Mehrazin Reza , Badani Ketan K. , Sfakianos John P. , Tsao Che-Kai , Wiklund Peter , Oh William K. , Cordon-Cardo Carlos , Tewari Ashutosh K. , Galsky Matthew D. , Kyprianou Natasha TITLE=The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic JOURNAL=Frontiers in Oncology VOLUME=11 YEAR=2021 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.734963 DOI=10.3389/fonc.2021.734963 ISSN=2234-943X ABSTRACT=

Coronavirus disease–2019 (COVID-19), a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, has become an unprecedented global health emergency, with fatal outcomes among adults of all ages throughout the world. There is a high incidence of infection and mortality among cancer patients with evidence to support that patients diagnosed with cancer and SARS-CoV-2 have an increased likelihood of a poor outcome. Clinically relevant changes imposed as a result of the pandemic, are either primary, due to changes in timing or therapeutic modality; or secondary, due to altered cooperative effects on disease progression or therapeutic outcomes. However, studies on the clinical management of patients with genitourinary cancers during the COVID-19 pandemic are limited and do little to differentiate primary or secondary impacts of COVID-19. Here, we provide a review of the epidemiology and biological consequences of SARS-CoV-2 infection in GU cancer patients as well as the impact of COVID-19 on the diagnosis and management of these patients, and the use and development of novel and innovative diagnostic tests, therapies, and technology. This article also discusses the biomedical advances to control the virus and evolving challenges in the management of prostate, bladder, kidney, testicular, and penile cancers at all stages of the patient journey during the first year of the COVID-19 pandemic.